Acute Myeloid Leukemia, in Relapse
Oncology·MeSH: Leukemia, Biphenotypic, Acute
Prevalence
6.0 / 100K
Incidence
4.3 / 100K/yr
1 drug in development·1 company·6 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| mt-401-ots | Marker Therapeutics, Inc. (MRKR) |
Frequently asked questions
How many drugs are in development for Acute Myeloid Leukemia, in Relapse?
BioSniper tracks 1 drug in development for Acute Myeloid Leukemia, in Relapse across 1 company.
How many clinical trials target Acute Myeloid Leukemia, in Relapse?
There are 6 clinical trials targeting Acute Myeloid Leukemia, in Relapse tracked by BioSniper.
What is the prevalence of Acute Myeloid Leukemia, in Relapse?
The estimated prevalence of Acute Myeloid Leukemia, in Relapse is approximately 6.0 per 100,000 population.
Deep-dive into Acute Myeloid Leukemia, in Relapse
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis